Key Sessions
Suzanne Topalian, MD
PD-1 Pathway Blockade: A Common Denominator for Cancer Therapy
Johns Hopkins Medicine
Bryan Briney, PhD
Antibody-guided Vaccine Design
The Scripps Research Institute
Joy Zuchero, PhD
Transport Vehicle: Utilizing the Brain Vasculature to Deliver CNS Therapeutics through Fc Engineering
Denali Therapeutics
David Baker, PhD
Design of New Protein Functions Using Deep Learning
University of Washington
MAIN CONFERENCE 12/16 - PT (Pacific Time, GMT-08:00)
MAIN CONFERENCE 12/16 - PT (Pacific Time, GMT-08:00)
7:00am - 8:00am60 mins
Registration and Breakfast
8:00am - 8:05am5 mins
Keynote Presentations
Co-Chairs' Welcome and Opening Remarks
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
- Katherine Harris, PhD - Chief Development Officer, Rondo Therapeutics
8:05am - 8:45am40 mins
Keynote Presentations
PD-1 Pathway Blockade: A Common Denominator for Cancer Therapy
- Suzanne Topalian, MD - Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine
8:45am - 9:25am40 mins
Keynote Presentations
Antibody-guided Vaccine Design
- Bryan Briney, PhD - Associate Professor, Department of Immunology and Microbiology, The Scripps Research Institute
9:25am - 10:05am40 mins
Keynote Presentations
Transport Vehicle: Utilizing the Brain Vasculature to Deliver CNS Therapeutics through Fc Engineering
- Joy Zuchero, PhD - Senior Director and Staff Scientist, Denali Therapeutics
10:05am - 10:35am30 mins
Keynote Presentations
Networking Refreshment Break
10:35am - 11:15am40 mins
Keynote Presentations
Design of New Protein Functions Using Deep Learning
- David Baker, PhD - Professor of Biochemistry and Director, Institute for Protein Design, University of Washington
11:15am - 11:45am30 mins
Keynote Presentations
Jim Huston Science Talent Award and Presentation: Sinking Influenza Viruses with Anchor-targeting Antibodies
- Jonathan Sockolosky, PhD - Senior Director, CSO Partner Team, Curie.Bio
- Katherine Harris, PhD - Chief Development Officer, Rondo Therapeutics
- Jenna Guthmiller, PhD - Assistant Professor, Department of Immunology, University of Colorado Anschutz Medical Campus
11:45am - 12:10pm25 mins
Keynote Presentations
Antibodies to Watch in 2025
- Janice Reichert, PhD - Director, Business Intelligence; Editor-in-Chief, The Antibody Society; mAbs
12:10pm - 12:15pm5 mins
Keynote Presentations
Transition to Scientific Luncheon Briefings
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 1
Writing the Future of Biologics with an Integrated Offering of Immunization, Libraries, and Machine Learning
- Colby Souders PhD - Chief Scientific Officer, Biopharma, Twist Bioscience
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 2
At-Line Nanoparticle-Based Antibody Molecular Structure Analyses
- Eric Bowen - Director of Product Management, Novilytic
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 3
Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds
- Yasmina Abdiche, PhD - Vice President, Exploratory Research, OmniAb
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 4
Accelerating Antibody Drug Discovery with GenScript's MonoRab™ & TurboCHO™ Platforms AND The Development of a Novel CD8-targeting Lipid Nanoparticle to Transiently Engineer CD8+ T Cells in vivo Using mRNA to Express a CD19 CAR
- Hui Foon Tan, PhD - Global Product Manager, GenScript
- Stuart Sievers, PhD - Senior Director, Discovery Research, Capstan Therapeutics
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 5
Custom Antibody Optimization in a Single Step
- Kalyani Mondal, PhD - Associate Director Protein Sciences/Analytics, Charles River Laboratories
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 6
Presentation Title TBA
- Jane Seagal, PhD - Vice President, Antibody Discovery, AlivaMab Biologics
1:15pm - 1:45pm30 mins
Scientific Briefing 1
Maximize AI Potential in Biologics Discovery and Development: from model Training to Consumption
- Nestor Vazquez Bernat, PhD - Head of Application Science, ENPICOM
1:15pm - 1:45pm30 mins
Scientific Briefing 2
Automated, Small-scale Transient Expression of Recombinant Antibodies in ExpiCHO and Expi293 Cell Lines for High-throughput Screening Applications
- Benjamin Gengenbach, Ph.D. - Staff Engineer - Bioprocess Automation, Thermo Fisher Scientific
1:15pm - 1:45pm30 mins
Scientific Briefing 3
Optimizing Antibodies and Related Protein Therapeutics: Bridging AI, Experimental Designs and Developability
- Sridhar Govindarajan, PhD - CIO and Co-Founder, ATUM
1:15pm - 1:45pm30 mins
Scientific Briefing 4
Design and Implementation of OmniHubTM, A Platform for Bioinformatics Tools Facilitating Antibody Discovery Workflows
- Swetha Garimalla, PhD - Director of Computational Immunology, OmniAb
1:15pm - 1:45pm30 mins
Scientific Briefing 5
Accelerating Bispecific Discovery with the Alloy Common Light Chain Fully Human Transgenic Mouse Platform
- Lucy Liu, PhD - Vice President, Head of Protein Science and Bioanalytics, Alloy Therapeutics
1:45pm - 2:15pm30 mins
Scientific Briefing 1
Strategies to Amplify the Therapeutic Potential of Rabbit-derived Antibodies
- Andra Li, Ph.D. - Scientific Director, IPA (ImmunoPrecise Antibodies)
1:45pm - 2:15pm30 mins
Scientific Briefing 2
Strategic Application of In Vitro Assays in Advancing Biotherapeutics for ADC, TCE, and Autoimmune Diseases
- Macy Jin, MD - Director, CRO Services, WuXi Biologics
1:45pm - 2:15pm30 mins
Scientific Briefing 3
Development of a NK Cell Engager Utilizing Antibodies Targeting a Single Amino Acid Variation
- Jordon Wang, Ph.D. - COO and SVP of Technology Development, AvantGen
1:45pm - 2:15pm30 mins
Scientific Briefing 4
Revolutionizing Therapeutic Antibody Engineering with Geneious-Luma: A Path to Next-Gen Multispecific Antibodies
- Christian Olsen - Associate VP, Industry Principal, Biologics, Dotmatics
1:45pm - 2:15pm30 mins
Scientific Briefing 5
Unlock a New Era of Automated Mini- and Maxi-Scale Plasmid Purification with AmMag™ Quatro Solutions
- Luciana Rosselli-Murai, PhD - Head of Field Application Scientist (FAS), Products and Instruments Division (USA and Europe), GenScript
2:25pm - 2:30pm5 mins
Track 1: Antibody-Based Degraders for Therapeutic Development
Co-Chairs' Remarks - Antibody-Based Degraders for Therapeutic Development
- Katherine Harris, PhD - Chief Development Officer, Rondo Therapeutics
- Jamie Spangler, PhD - Associate Professor, Johns Hopkins University
2:25pm - 2:30pm5 mins
Track 2: Forward and Reverse Translation in Antibody Research
Co-Chairs’ Remarks - Forward and Reverse Translation in Antibody Research
- Jyothsna Visweswaraiah, PhD - Director, Biotherapeutics Drug Creation, Seismic Therapeutic
- Sara Colombetti, PhD - Global Head of Oncology Discovery Pharmacology, Roche Innovation Center Zürich
2:30pm - 3:00pm30 mins
Track 1: Antibody-Based Degraders for Therapeutic Development
Targeted Membrane and Extracellular Protein Degradation via Transferrin Receptor
- Xin Zhou, Ph.D. - Assistant Professor of Biological Chemistry & Mole, Dana-Farber & Harvard Medical School
2:30pm - 3:00pm30 mins
Track 2: Forward and Reverse Translation in Antibody Research
Optimising Immunostimulatory Antibodies for Cancer Therapy
- Sean Lim, Ph.D. - Professor of Haematology & Translational Immunolog, University of Southampton
3:00pm - 3:30pm30 mins
Track 1: Antibody-Based Degraders for Therapeutic Development
Antibody-mediated Delivery of Chimeric Protein Degraders
- Thomas Pillow, PhD - Distinguished Scientist, Genentech
3:00pm - 3:30pm30 mins
Track 2: Forward and Reverse Translation in Antibody Research
The Therapeutic Potential of IgE and IgE-derived Antibodies
- Kevin Fitzgerald, PhD. - Chief Scientific Officer, Epsilogen
3:30pm - 4:00pm30 mins
Track 1: Antibody-Based Degraders for Therapeutic Development
Degrader Antibody Conjugates - Reimagined ADCs for Oncology and Beyond
- Bernhard H. Geierstanger, Ph.D. - Co-founder and Chief Technology Officer, Firefly Biologics
3:30pm - 4:00pm30 mins
Track 2: Forward and Reverse Translation in Antibody Research
The FORCE Platform Leverages TfR1 for Delivery of Potentially Disease-modifying Therapeutics to Treat Muscle Diseases
- Tama Evron, Ph.D - Director, Platform Discovery, Dyne Therapeutics
4:00pm - 4:45pm45 mins
Networking Refreshment Break, Exhibit and Poster Viewing
- Weisheng Chen, PhD - Founder and CEO, Leveragen
4:45pm - 5:15pm30 mins
Track 1: Antibody-Based Degraders for Therapeutic Development
EpiTACs Are a Novel Bispecific Antibody Platform that Drive the Degradation of Disease-Driving Targets
- Shyra Gardai, Ph.D. - Chief Scientific Officer, EpiBiologics
4:45pm - 5:15pm30 mins
Track 2: Forward and Reverse Translation in Antibody Research
Presentation Title TBA
- Christine Moussion, PhD - Senior Principal Scientist and Group Head, Cancer Immunotherapy Discovery, Genentech
5:15pm - 5:45pm30 mins
Track 1: Antibody-Based Degraders for Therapeutic Development
Single Domain Antibodies as Therapy for Tauopathies and Synucleinopathies
- Einar Sigurdsson, PhD - Professor, Department of Neuroscience and Physiology Department of Psychiatry, NYU Grossman School of Medicine
5:15pm - 5:45pm30 mins
Track 2: Forward and Reverse Translation in Antibody Research
Checkpoint Flexible Dimer Biology, Novel Pathways, and Forward Translation
- Jun Wang, Ph.D. - Assistant Professor, Department of Pathology, NYU Grossman School of Medicine
5:45pm - 6:15pm30 mins
Track 1: Antibody-Based Degraders for Therapeutic Development
Lysosomal Targeting Chimeras for the Degradation of Extracellular Proteins
- Steve Staben - Chief Scientific Officer, Lycia Therapeutics
5:45pm - 6:15pm30 mins
Track 2: Forward and Reverse Translation in Antibody Research
CD19 Targeted CD28 Agonism: Learnings from Forward and Reverse Translation Approaches
- Sara Colombetti, PhD - Global Head of Oncology Discovery Pharmacology, Roche Innovation Center Zürich
6:15pm - 7:45pm90 mins
Opening Night Networking Reception, Exhibits and Poster Viewing
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.